Bluebird Bio (BLUE) Receives a Buy from Maxim Group

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Bluebird Bio (BLUEResearch Report), with a price target of $130.00. The company’s shares closed last Monday at $76.60, close to its 52-week low of $71.42.

According to TipRanks.com, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -19.5% and a 26.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Hancock Jaffe Laboratories, and Lineage Cell Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bluebird Bio with a $116.63 average price target, a 40.7% upside from current levels. In a report issued on November 26, Leerink Partners also upgraded the stock to Buy with a $119.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $163.43 and a one-year low of $71.42. Currently, Bluebird Bio has an average volume of 977.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.